EMA’s CHMP backs six new products in January

At its January meeting, CHMP recommended six new drugs and vaccines, including a rare post-reexamination reversal, backing Sanofi’s ROCK2 inhibitor Rezurock belumosudil to treat chronic graft-versus-host disease (GvHD) in ages twelve and up.

CHMP’s Rezurock recommendation is for conditional marketing authorization. Sanofi (Euronext:SAN; NASDAQ:SNY) received FDA approval of the drug in 2021 for chronic GvHD after failure of at least two prior lines of therapy. ...